STOCK TITAN

Vigil Neuroscience Inc - VIGL STOCK NEWS

Welcome to our dedicated news page for Vigil Neuroscience (Ticker: VIGL), a resource for investors and traders seeking the latest updates and insights on Vigil Neuroscience.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vigil Neuroscience's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vigil Neuroscience's position in the market.

Rhea-AI Summary
Vigil Neuroscience, Inc. presents key findings from the ILLUMINATE Natural History Study and the IGNITE Phase 2 study at the 2024 American Academy of Neurology Annual Meeting. The studies demonstrate the potential of iluzanebart (VGL101) as a disease-modifying therapy for Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP). Positive interim data show promising results in slowing neurodegeneration and improving clinical outcomes. The findings suggest that MRI and fluid biomarkers could be important measures of ALSP pathophysiology. Vigil aims to advance the development of iluzanebart to offer a transformative treatment for ALSP patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.82%
Tags
none
-
Rhea-AI Summary
Vigil Neuroscience, Inc. reported positive interim data from Phase 2 IGNITE trial for iluzanebart (VGL101) in ALSP patients. Enrollment completed with 20 patients, next data readout in Q3 2024. Phase 1 trial for VG-3927 ongoing. Appointed Petra Kaufmann, M.D., M.S., F.A.A.N, as Chief Medical Officer. Financial results for Q4 2023 showed $117.9 million cash position.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7%
Tags
-
Rhea-AI Summary
Vigil Neuroscience, Inc. appoints Dr. Petra Kaufmann as Chief Medical Officer, bringing extensive experience in neurology and rare diseases. Dr. Kaufmann's background includes leadership roles at Affinia Therapeutics and Novartis Gene Therapies. She will lead the development of iluzanebart and VG-3927, aiming to advance treatments for neurological diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.18%
Tags
management
Rhea-AI Summary
Vigil Neuroscience, Inc. (Nasdaq: VIGL) announced oral and poster presentations at the 2024 AAN Annual Meeting on April 13-18, 2024. The presentations focus on VGL101, an immunotherapy for Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP). Key speakers include Zbigniew Wszolek, M.D., David S. Lynch, M.D., Ph.D., and Abbie Renoux, Ph.D.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.68%
Tags
conferences
-
Rhea-AI Summary
Vigil Neuroscience, Inc. (Nasdaq: VIGL) announced Ivana Magovčević-Liebisch, Ph.D., J.D., President will participate in a fireside chat at Stifel 2024 Virtual CNS Days. The event will be on March 19th at 3:30 p.m. E.T. The webcast will be available on the Company’s website for 90 days post-presentation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.99%
Tags
conferences
-
Rhea-AI Summary
Vigil Neuroscience, Inc. presents preclinical data on VG-3927 at AD/PD™ 2024 International Conference, highlighting its potential for treating neurodegenerative diseases like Alzheimer's Disease (AD) due to its unique neuroprotective profile and ability to modulate microglia activation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.28%
Tags
none
Rhea-AI Summary
Vigil Neuroscience, Inc. presented a poster at the 2024 ACTRIMS Forum highlighting the clinical overlap of ALSP and multiple sclerosis, emphasizing the importance of genetic testing. The analysis revealed challenges in accurate diagnosis, with only 24.7% initially diagnosed correctly. Barriers to genetic testing include uncertainties, fear of results, financial impact, and care management challenges.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.59%
Tags
none
-
Rhea-AI Summary
Vigil Neuroscience, Inc. announced the participation of its President and CEO, Ivana Magovčević-Liebisch, and Chief Science Officer, David Gray, in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference. The webcast will be available on the company's website, and an archived webcast will be accessible for approximately 90 days after the presentation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.35%
Tags
conferences
-
Rhea-AI Summary
Vigil Neuroscience, Inc. (Nasdaq: VIGL) extends projected cash runway into second half of 2025. The company is on track to report interim Phase 1 data for VG-3927 in healthy volunteers in mid-2024 and Phase 2 results from IGNITE clinical trial evaluating iluzanebart in Q3 2024. The company presented at J.P. Morgan Healthcare Conference on January 11, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.51%
Tags
none
Rhea-AI Summary
Vigil Neuroscience, Inc. (VIGL) to participate in fireside chat at Evercore ISI 6th Annual HealthCONx Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Vigil Neuroscience Inc

Nasdaq:VIGL

VIGL Rankings

VIGL Stock Data

118.77M
16.21M
9.32%
85.64%
2.68%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Watertown

About VIGL

vigil neuroscience is the world’s first microglia-focused therapeutics company. our purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of the microglia, the sentinel cells of the brain’s immune system. we are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and their families.